Study guide

11.1 Safety Communications, Reconciliation and Follow-Up

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

11.1 Safety Communications, Reconciliation and Follow-Up

Key Takeaways Explain This Topic AI

Authority, ethics and investigator reporting channels can have different applicable requirements.

Cumulative safety findings may require rapid communication beyond individual SUSAR cases.

Common data concepts should reconcile, with justified differences documented.

Last updated: October 2026

Safety Communications, Reconciliation and Follow-Up

CRAs and clinical data managers conduct rigorous SAE reconciliation between these two systems:

Term Congruence: Check whether both systems describe the same clinical event. Different structures, coding versions or levels of detail may be legitimate when documented and reconciled.

Date Matching: The date of event onset, date of site awareness, and date of event resolution should agree where they represent the same concept, with justified differences documented.

Criteria Alignment: The seriousness criteria checked on the eCRF (e.g., hospitalization) must match the criteria registered in the pharmacovigilance system.

Severity and Causality: Both systems must reflect the investigator's recorded assessment of severity and causality with any justified difference explained.

Cross-Referencing Source Notes for Timeliness Compliance

The CRA reviews appropriate records and communications to evaluate immediate reporting and the actual protocol-defined deadline:

Compare the date and time on hospital admission notifications or clinical progress notes against the transmission timestamp on the initial SAE notification form sent to the sponsor.

For example, a protocol requiring initial notification within 24 hours would not be met by awareness on Monday at 09:00 and initial transmission Thursday at 16:00. Evaluate any permitted exception, participant impact and the reporting process; classify the finding under the trial’s method. The CRA documents the deviation in the monitoring report, reviews it during the investigator debriefing, and ensures an appropriate CAPA is executed.

Safety communications and signal evaluation

Follow the distribution plan and applicable reporting requirements for safety notifications to investigators and IRBs/IECs. Authority reporting deadlines do not automatically establish an identical ethics committee deadline. Confirm investigator receipt and review, assess whether the information affects consent or protocol conduct, and preserve the communication in the appropriate file. An ISF section number is a sponsor filing convention, not a universal rule.

Pharmacovigilance combines individual case assessment with cumulative review. Expected serious reactions, increased event rates, lack of efficacy in a life-threatening disease, and major new nonclinical findings can require rapid communication even without a new individual SUSAR. E2A explicitly recognises these other observations. A classification algorithm supports judgement; it does not replace medical and scientific evaluation.

A Data Monitoring Committee (DMC/IDMC/DSMB) may recommend continuation, modification or stopping after reviewing safety and relevant efficacy data. Its charter defines composition, access, schedule and decision process. Not every trial requires a DMC, and safety concerns need not reach statistical significance before action. The sponsor documents its response; the CRA verifies site implementation while maintaining the blind for personnel who should not receive treatment identities.

Comparing reporting channels

Route Trigger and governing instruction Timing

Investigator to sponsor SAE; protocol-defined exceptions may apply Immediately after reasonable awareness; use the actual protocol deadline

Sponsor to authority Fatal/life-threatening unexpected suspected reaction As soon as possible, within 7 calendar days; follow-up within 8 additional days

Sponsor to authority Other serious unexpected suspected reaction As soon as possible, within 15 calendar days after minimum criteria are met

Investigator/sponsor to IRB/IEC Safety information and changes required by the applicable framework Follow applicable requirements and committee procedures

DMC to sponsor Safety/efficacy review and recommendations Charter schedule and urgent procedures

The clocks serve different purposes. A site cannot wait 15 days to notify the sponsor merely because a sponsor authority report may have a 15-day maximum. A sponsor cannot postpone a qualifying expedited report until the next DMC meeting. Keep awareness dates, initial transmissions, follow-up and receipt acknowledgements traceable.

Stopping treatment and leaving a trial are different decisions

A participant may stop the investigational product, discontinue an assessment, withdraw consent for some activities or leave all further trial follow-up. These outcomes should not be collapsed into a single checkbox. E6(R3) expects protocol-based handling of the end of participation, respectful communication and appropriate care. Reliable records describe what the person decided and what the investigator determined, including the scope of any continuing permission.

A protocol may require permanent discontinuation for a safety finding, allow a temporary hold, or permit continued outcome follow-up after product cessation. The investigator makes the clinical decision within the protocol and applicable requirements. The CRA verifies the evidence, authorised process and reporting; they do not unilaterally stop treatment or insist on continued participation to protect a study endpoint.

Reconciling dates without erasing their meaning

An event can begin before admission, be reported to the investigator later and reach the sponsor on another date. Those dates need not equal one another. Reconcile each field to its defined concept and supporting evidence. If two systems intentionally collect different concepts, document the mapping rather than forcing equality. If they collect the same onset date and disagree, obtain supported clarification. The investigator and sponsor can also have different causality assessments; preserve each assessment and apply the reporting standard rather than overwriting one opinion to make the databases look identical.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E2A , WMA Declaration of Helsinki, 2024 .